Vancomycin: A 50-year reassessment

Clinical Infectious Diseases

Volumn 42, Issue SUPPL. 1, 2006, Pages

  Moellering Jr , Robert C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BACTERICIDAL ACTIVITY; BORNEO; DRUG ISOLATION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOMYCES; VANA GENE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; HISTORY, 20TH CENTURY; HUMANS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 29244453639     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/491708     Document Type: Editorial

References (10)

1. Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981; 3:S200-4.
2. Brummett RE. Effects of antibiotic-diuretic interactions in the guinea pig model of ototoxicity. Rev Infect Dis 1981; 3:S216-23.
3. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23:138-41.
4. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94:343-6.
5. Reassessments of vancomycin - a potentially useful antibiotic. Rev Infect Dis 1981; 3:S190-300.
6. Leclerq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157-61.
7. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
8. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-39.
9. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of minimal inhibitory concentration (MIC) and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.